Cell4Pharma

Cell4pharma To establish sufficient study material, the primary tubule cells were immortalized via a technique proven to be successful in other cell types. The group lead by Prof. Dr. Van Den Heuvel and Prof. Dr. Levtchenko succeeded in their endeavors and ciPTEC was born.

Cell4Pharma aims to reduce the failure rate in late clinical stages due to renal tox below 3% market wide within the next 10 years. Without the use of animal experimentation. This ambition is supported by our human renal cell line ciPTEC validated during extensive collaborations with the pharmaceutical industry.

Due to renal toxicity 20% of compounds fail during clinical stages of drug development.

To get more successful drugs to market, we empower researchers to accurately identify and eliminate nephro-toxic compounds during preclinical stages of drug development.

ciPTEC is a human renal cell line that mimics the proximal tubule cells of the kidney. These cells are a main target for drug-induced kidney injury, caused by their role in highly efficient transport of drugs and toxic compounds from the bloodstream into urine. The most relevant drug transporter proteins involved in this process are stably and functionally expressed in our cell models.

If you want more information on how it can help in your research or a quote, contact us: